Moderna price target raised to $139 from $107 at Goldman Sachs
Goldman Sachs analyst Salveen Richter raised the firm's price target on Moderna to $139 from $107 and keeps a Buy rating on the shares. The stock closed Tuesday down $2.47 to $98.56. The final analysis of the company's Phase 3 study of its COVID-19 vaccine, mRNA-1273, is expected imminently, with Emergency Use Authorization likely to follow as soon as December, Richter tells investors in a research note. The analyst estimates Moderna will generate revenue of $305M and $13.3B in Q4 and 2021, respectively, from mRNA-1273. Post the interim data that demonstrated efficacy of 94.5%, investor focus shifts to supply contracts, manufacturing and distribution, says Richter. The analyst believes Moderna remains on track to deliver 500M or up to 1B doses per year, beginning in 2021.
MRNA Moderna
Moderna initiated with an Equal Weight at Wells Fargo
Inovio on 'top-10 vaccine contenders list,' says Benchmark
Lawsuit alleges Amazon drives up price of e-books, WSJ reports » 17:28
A lawsuit filed in a…
A lawsuit filed in a federal district court in New York is accusing Amazon of forcing customers on other book sites to pay too much for electronic books, the Wall Street Journal's Jeffrey A. Trachtenberg and Dana Mattioli report. The suit alleges that an agreement between Amazon and five major book publishers has led to higher e-book prices for all consumers, since it prevents competing retails from selling any of these publishers' e-books at a lower price than on the ecommerce giant's site, the authors say. The suit is seeking class-action status and claims that Amazon charges high commissions and other costs to publishers, the authors note. Reference Link
Ring Neighbors app security flaw exposed users' exact locations, TechCrunch says
AHPI
AKAM
CBAY